Hairy cell leukemia: treatment prospects.
The recent advances in the management of hairy cell leukemia, a chronic and indolent B-cell lymphoproliferative disorder are reviewed. The introduction of alpha-interferon, purine analogs and recombinant monoclonal antibodies/immunotoxins has dramatically improved the outcome in a disease that once had a dismal prognosis. The underlying genetic defect remains unknown.
Repatriation General Hospital, Daws Road, Daw Park, South Australia 5041. prabha.seshadri@rgh.sa.gov.au
P
P
Seshadri
R
R
Seshadri
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D007943:Leukemia, Hairy Cell / Q000235:genetics / Q000628:therapy*; D011379:Prognosis; D011687:Purines / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D016898:Interferon-alpha; D011687:Purines